Table 4 Comparison of biomarkers between patients and controls for all samples and for only the first sample after admission
From: IL-6 and cfDNA monitoring throughout COVID-19 hospitalization are accurate markers of its outcomes
All samples | Patients N = 201 | Controls N = 55 | p |
|---|---|---|---|
TNF-α (pg/mL) | 40.02 [34.83; 47.41] | 41.07 [38.56; 44.99] | 0.156 |
IL-8 (pg/mL) | 54.29 [40.43; 89.22] | 56.21 [43.26; 107.75] | 0.412 |
IL-1β (pg/mL) | 55.90 [47.80; 66.92] | 59.91 [54.04; 62.24] | 0.238 |
IFN-γ (pg/mL) | 145.84 [123.72; 176.59] | 134.60 [128.65; 142.43] | 0.004 |
IL-17A (pg/mL) | 19.40 [14.73; 23.90] | 21.31 [18.48; 21.31] | 0.204 |
P-Selectin (ng/mL) | 55.48 [42.12; 73.30] | 77.44 [67.55; 84.99] | < 0.001 |
G-CSF (pg/mL) | 143.97 [123.70; 159.45] | 130.47 [124.32; 138.97] | < 0.001 |
IL-6 (pg/mL) | 20.41 [4.34; 51.62] | 7.80 [5.15; 10.42] | 0.004 |
cfDNA (ng/mL) | 7.87 [4.45; 14.40] | 2.56 [1.71; 3.61] | < 0.001 |
1st samples | Patients N = 93 | Controls N = 55 | p |
|---|---|---|---|
TNF-α (pg/mL) | 38.51 [32.58; 45.34] | 41.07 [38.56; 44.99] | 0.013 |
IL-8 (pg/mL) | 47.45 [33.71; 66.16] | 56.21 [43.26; 107.75] | 0.010 |
IL-1β (pg/mL) | 51.66 [43.09; 59.90] | 59.91 [54.04; 62.24] | < 0.001 |
IFN-γ (pg/mL) | 134.40 [119.97; 159.07] | 134.60 [128.65; 142.43] | 0.846 |
IL-17A (pg/mL) | 18.48 [10.79; 22.80] | 21.31 [18.48; 21.31] | 0.001 |
P-Selectin (ng/mL) | 52.21 [35.63; 71.42] | 77.44 [67.55; 84.99] | < 0.001 |
G-CSF (pg/mL) | 142.57 [120.38; 162.04] | 130.47 [124.32; 138.97] | 0.041 |
IL-6 (pg/mL) | 30.52 [6.26; 62.51] | 7.80 [5.15; 10.42] | < 0.001 |
cfDNA (ng/mL) | 7.68 [4.23; 14.49] | 2.56 [1.71; 3.61] | < 0.001 |